Alliances
Epigenomics AG today has decided to terminate its collaboration with its Chinese partner BioChain for the licensing of the Septin9 marker and the exclusive distribution rights in China for Epi proColon
GeoVax Labs, Inc., a biotechnology company developing human vaccines, announced today that it has expanded its collaboration activities with Leidos, Inc.
Abpro, based in Woburn, Mass., inked a deal worth up to $4 billion with China-based Nanjing Chia Tai Tianqing Pharmaceutical Company, known as NJCTTQ, a global pharmaceutical company.
Abpro eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royalties
Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough.
Contributing Further to Patients With Mycetoma, a Neglected Tropical Disease
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
Bristol-Myers Squibb and South San Francisco-based CytomX Therapeutics have been collaborating since 2014, a deal that was boosted in 2017 when Bristol-Myers Squibb added up to eight additional targets using CytomX’s Probody platform.
In a New Public Service Announcement, Foley Reveals for the First Time his Personal Story of Caring for his Mother Following Ovarian Cancer Recurrence
The drug is being developed and commercialized jointly by AstraZeneca and Merck. It has already been approved for multiple indications in advanced ovarian cancer and metastatic breast cancer.
PRESS RELEASES